• Skuldtech has received funding from national and international anti-doping agencies (WADA, USADA, AFLD) to identify and validate in a clinical setting the biomarkers associated with erythropoietin (EPO) drug abuse.

• Skuldtech and Roche Diagnostics have issued in 2006 an Application Note concerning rapid and accurate gene profiles determined with the "Genome Sequencer System" developed by 454 Life Sciences.

• Since 2007, Skuldtech has received grants from the European Union for new diagnosis development, the analysis of animal venom as new drug leads (in collaboration with the J. Craig Venter Institute) and for the study of host-pathogenic interactions in the leishmania case.

• Skuldtech is partner of GSO Canceropole, EuroBioMed, Q@limed and Biomeridies, French bioclusters of excellence in Human Health and Life Sciences.